BELLEVUE, Wash., July 11, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (PINK: SCLR) today announced that the European Patent Office has issued a patent covering SCOLR’s oral modified release ibuprofen formulation, which is based on SCOLR’s CDT® Controlled Delivery Technology platform.
European patent number 1,793,809 covers SCOLR’s approach for optimizing the release profile of ibuprofen, in order to achieve particular blood level concentrations of this active ingredient for a therapeutic purpose.
Stephen Turner, President and CEO of SCOLR, said: “The grant of this patent expands our ibuprofen-related intellectual property portfolio while providing potential value to this product for our future partners. Although our business and available resources are focused on growing our nutritional products business into a sustainable source of revenue, we believe that this patent enhances the global market opportunity for our 12-hour ibuprofen formulation and we intend to continue to seek appropriate partnership opportunities for the commercialization of the product.”
About SCOLR Pharma:
Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call (425) 368-1050 or visit http://www.scolr.com/.
Forward looking statements:
Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding growth of SCOLR’s nutritional business, market opportunities related to SCOLR’s ibuprofen product, potential partnership opportunities and potential commercialization of SCOLR’s ibuprofen product. Factors that could cause these forward-looking statements to differ from actual results include adverse consumer or retailer reception of SCOLR’s products, unfavorable regulatory determinations, competitive factors and other risks and uncertainties discussed in the company’s periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.
Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050
SOURCE SCOLR Pharma, Inc.
